Clinical features and survival outcomes of unclassified high-grade neuroendocrine carcinoma of the lung
Background: Differentiating high-grade neuroendocrine carcinomas (HGNEC) is difficult. We aimed to assess the clinical features and survival outcomes of unclassified HGNEC (uHGNEC) and to compare it with small-cell lung cancer (SCLC). Material and Methods: This was a retrospective and observational...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sakarya University
2023-06-01
|
| Series: | Sakarya Tıp Dergisi |
| Subjects: | |
| Online Access: | https://dergipark.org.tr/tr/download/article-file/3060201 |
| _version_ | 1797350422963290112 |
|---|---|
| author | Funda Demirağ Ülkü Yılmaz Suna Kavurgacı Pınar Akın Kabalak Yasemin Söyler |
| author_facet | Funda Demirağ Ülkü Yılmaz Suna Kavurgacı Pınar Akın Kabalak Yasemin Söyler |
| author_sort | Funda Demirağ |
| collection | DOAJ |
| description | Background: Differentiating high-grade neuroendocrine carcinomas (HGNEC) is difficult. We aimed to assess the clinical features and survival outcomes of unclassified HGNEC (uHGNEC) and to compare it with small-cell lung cancer (SCLC).
Material and Methods: This was a retrospective and observational study of HGNEC patients. Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS). Cox-regression analyses were used to determine the risk factors independently associated with PFS and OS.
Results: One hundred twenty-one patients [uHGNEC (n = 35), SCLC (n = 86)] were analysed. The primary tumour was mostly right-sided, located in the centre of the lungs. The IASLC stage at diagnosis was locally advanced in 43 (35.5%) patients and advanced in 78 (64.5%) patients. uHGNEC and SCLC groups shared similar clinical features. The study population's median PFS and OS were 8.8 (95%Cl 7.29 – 10.30) and 10.9 (95%Cl 9.9 – 11.8) months, respectively. uHGNEC- and SCLC groups had a similar PFS (9.4 vs 8.6 months, p = 0.99) and OS (12 vs 10.7 months, p = 0.51). The six-month, one- and two-year PFS and OS of two groups were also similar. Among all patients, a right-sided tumour (HR: 1.558, 95%Cl 1.044 – 2.325, p = 0.03) and advanced-stage disease (HR: 1.928, 95%Cl 1.292 – 2.877, p = 0.001) were prognostic factors for poor OS. Cox-regression analysis indicated that histopathology did not have an impact on PFS and OS.
Conclusion: HGNEC patients who cannot be classified pathologically behave like SCLC. |
| first_indexed | 2024-03-08T12:44:40Z |
| format | Article |
| id | doaj.art-b6bf87df638d43aeb425cd32efb38104 |
| institution | Directory Open Access Journal |
| issn | 2146-409X |
| language | English |
| last_indexed | 2024-03-08T12:44:40Z |
| publishDate | 2023-06-01 |
| publisher | Sakarya University |
| record_format | Article |
| series | Sakarya Tıp Dergisi |
| spelling | doaj.art-b6bf87df638d43aeb425cd32efb381042024-01-21T07:40:09ZengSakarya UniversitySakarya Tıp Dergisi2146-409X2023-06-0113229530410.31832/smj.127725928Clinical features and survival outcomes of unclassified high-grade neuroendocrine carcinoma of the lungFunda Demirağ0Ülkü Yılmaz1Suna Kavurgacı2Pınar Akın Kabalak3Yasemin Söyler4Ankara Ataturk Sanatorium Training and Research Hospital, Department of PathologyAnkara Ataturk Sanatorium Training and Research Hospital, Department of Chest DiseasesAnkara Ataturk Sanatorium Training and Research Hospital, Department of Chest DiseasesAnkara Ataturk Sanatorium Training and Research Hospital, Department of Chest DiseasesAnkara Ataturk Sanatorium Training and Research Hospital, Department of Chest DiseasesBackground: Differentiating high-grade neuroendocrine carcinomas (HGNEC) is difficult. We aimed to assess the clinical features and survival outcomes of unclassified HGNEC (uHGNEC) and to compare it with small-cell lung cancer (SCLC). Material and Methods: This was a retrospective and observational study of HGNEC patients. Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS). Cox-regression analyses were used to determine the risk factors independently associated with PFS and OS. Results: One hundred twenty-one patients [uHGNEC (n = 35), SCLC (n = 86)] were analysed. The primary tumour was mostly right-sided, located in the centre of the lungs. The IASLC stage at diagnosis was locally advanced in 43 (35.5%) patients and advanced in 78 (64.5%) patients. uHGNEC and SCLC groups shared similar clinical features. The study population's median PFS and OS were 8.8 (95%Cl 7.29 – 10.30) and 10.9 (95%Cl 9.9 – 11.8) months, respectively. uHGNEC- and SCLC groups had a similar PFS (9.4 vs 8.6 months, p = 0.99) and OS (12 vs 10.7 months, p = 0.51). The six-month, one- and two-year PFS and OS of two groups were also similar. Among all patients, a right-sided tumour (HR: 1.558, 95%Cl 1.044 – 2.325, p = 0.03) and advanced-stage disease (HR: 1.928, 95%Cl 1.292 – 2.877, p = 0.001) were prognostic factors for poor OS. Cox-regression analysis indicated that histopathology did not have an impact on PFS and OS. Conclusion: HGNEC patients who cannot be classified pathologically behave like SCLC.https://dergipark.org.tr/tr/download/article-file/3060201yüksek dereceli nöroendokrin karsinomaküçük hücreli akciğer kanserinöroendokrin tümörlerhigh-grade neuroendocrine carcinomapulmonary neuroendocrine carcinomassmall-cell lung cancer |
| spellingShingle | Funda Demirağ Ülkü Yılmaz Suna Kavurgacı Pınar Akın Kabalak Yasemin Söyler Clinical features and survival outcomes of unclassified high-grade neuroendocrine carcinoma of the lung Sakarya Tıp Dergisi yüksek dereceli nöroendokrin karsinoma küçük hücreli akciğer kanseri nöroendokrin tümörler high-grade neuroendocrine carcinoma pulmonary neuroendocrine carcinomas small-cell lung cancer |
| title | Clinical features and survival outcomes of unclassified high-grade neuroendocrine carcinoma of the lung |
| title_full | Clinical features and survival outcomes of unclassified high-grade neuroendocrine carcinoma of the lung |
| title_fullStr | Clinical features and survival outcomes of unclassified high-grade neuroendocrine carcinoma of the lung |
| title_full_unstemmed | Clinical features and survival outcomes of unclassified high-grade neuroendocrine carcinoma of the lung |
| title_short | Clinical features and survival outcomes of unclassified high-grade neuroendocrine carcinoma of the lung |
| title_sort | clinical features and survival outcomes of unclassified high grade neuroendocrine carcinoma of the lung |
| topic | yüksek dereceli nöroendokrin karsinoma küçük hücreli akciğer kanseri nöroendokrin tümörler high-grade neuroendocrine carcinoma pulmonary neuroendocrine carcinomas small-cell lung cancer |
| url | https://dergipark.org.tr/tr/download/article-file/3060201 |
| work_keys_str_mv | AT fundademirag clinicalfeaturesandsurvivaloutcomesofunclassifiedhighgradeneuroendocrinecarcinomaofthelung AT ulkuyılmaz clinicalfeaturesandsurvivaloutcomesofunclassifiedhighgradeneuroendocrinecarcinomaofthelung AT sunakavurgacı clinicalfeaturesandsurvivaloutcomesofunclassifiedhighgradeneuroendocrinecarcinomaofthelung AT pınarakınkabalak clinicalfeaturesandsurvivaloutcomesofunclassifiedhighgradeneuroendocrinecarcinomaofthelung AT yaseminsoyler clinicalfeaturesandsurvivaloutcomesofunclassifiedhighgradeneuroendocrinecarcinomaofthelung |